According to Reuters, a recent study shows that older people with cancer reacts to its strongest new medicines despite the age -of -the -art changes in their immunity.
In a statement, in a statement, in a statement, in a statement, in a statement, in the response of the immune system of the Drugs, in a statement, in the “resistors” of patients in patients, in a statement, in a statement, in a statement, in a statement, in a statement, in a statement, in a statement, in a statement, in a statement, in a statement, Chief Study Officer, Jones Hopkins University, in a statement, in a statement. Immune obstacles.
Researchers analyzed the immune system’s indicators in the blood samples of nearly 100 patients with cancer treated with immune barriers, and half of them were at least 65 years old.
Immunotherapy drugs are widely used for the effect of “checkpoints” or a barrier proteins before the response of the immune system.
In practice, drugs release “brakes” for the immune system, which allows T -cells to identify and attack cancer cells more effectively.
Drugs Shades include “Citruda” built by “Merk & Co”, as well as “Obedivo” from the “Roche” company “Bristol Myers Stipe” and “Tesenteric”.
The study, published on Monday in the Journal of “Nature Communicens”, showed that young and adult patients benefited the same well as the treatment well.
It is achieved in elderly patients, although the production of inflammatory protein compounds and natural activities, known as “cytokins” or their weakness.
Older patients also have fewer immune cells, but “worn” called “innocent” T cells.
Researchers have noticed that “t -cells of t -cells” in older patients are already targeted for experimental cancer drugs in the research process.
They say that the innocent T -cells that are being developed by companies such as “Roche”, “Bristol Maires” and “Astrazzinica” are drugs that prevent it. The elderly can provide a potential advantage.
